chartexchange

Palatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeek® 2026

PR Newswire | Nov 16, 2026 7:30 AM EST

Novel peptide and long-acting lipidated peptide agonists demonstrate potent MC4R activity with minimal to no MC1R activity, supporting the potential to substantially reduce or eliminate hyperpigmentation Significant reductions in body weight and food intake demonstrated in preclinical...

Read original article